Scientists Develop Promising Molecule to Target Hidden Cancer Stem Cells, Reduce Risk of Recurrence

In recent decades, significant progress has been made in cancer treatment, yet one of the most feared challenges remains: cancer recurrence. Many patients feel relieved after surgery, chemotherapy, or radiation, only to face a return of the disease years later. Researchers have long sought to understand why.

Experts now point to a small but dangerous group of cells called **cancer stem cells** as a major reason for recurrence. Unlike most cancer cells that grow rapidly and are targeted by chemotherapy, these stem cells “hide” in the body, remaining dormant for years. When chemotherapy kills rapidly dividing cells, these dormant stem cells survive and can later reactivate, forming new tumors.

At the forefront of this research is **Professor Amish Desai** of Virginia Commonwealth University, who has spent 30 years studying complex sugar molecules in the body that could provide a solution. His work focuses on **glycosaminoglycans (GAGs)**, natural sugar chains that cover nearly every human cell and play roles in blood clotting, inflammation, cell growth, and communication.

Professor Desai believed that glycosaminoglycans could serve not only as natural protective layers but also as the basis for new drugs. While natural GAGs like heparin are already used as blood thinners, variations in quality and side effects posed challenges. To address this, Desai’s lab developed **synthetic, safe versions of GAGs**, leading to the creation of a new molecule called **G2.2**, developed in collaboration with colorectal and gastrointestinal cancer specialist Dr. Bhumika Patel.

G2.2 works differently than conventional chemotherapy. Professor Desai compares cancer stem cells to hibernating bears: they stay protected in their “dens” and evade threats. G2.2 interacts with specific receptors on these stem cells, activating signals that induce **cell death**, effectively eliminating them.

Laboratory tests have shown that G2.2 can **almost completely eradicate dormant stem cells** in colorectal cancer models. Promising results were also observed in lung, brain, kidney, and pancreatic cancer models, suggesting broad potential across tumor types. Early experiments indicate that G2.2 is **safe**, shows minimal toxic effects, and even boosts the immune system by activating T-cells, which naturally fight cancer.

Currently in **preclinical trials**, G2.2 represents a new hope in cancer treatment. Unlike conventional therapies that target rapidly growing tumors, this molecule attacks the hidden “roots” of cancer, potentially preventing recurrence and offering patients a better long-term prognosis.